Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239681 · ClinicalTrials.gov registry record · Phase 3
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17,802
- Enrollment target
NCT00239681 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 17,802 participants.
The verdict
NCT00239681, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17,802 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.
Interventions
- OTHER Placebo
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,802 participants |
| Start Date | 2003-02 |
| Est. Completion | 2008-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00239681
The ClinicalTrials.gov registry entry for NCT00239681 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 17,802 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00239681 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00239681 about?
NCT00239681 is a clinical study titled "JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events". The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.
What is the current status of trial NCT00239681?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17,802 participants. The study started on 2003-02. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00239681?
The interventions under investigation include: Placebo (OTHER), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT00239681?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.